WO2005042712A3 - Heterocyclic compounds and methods of making and using thereof - Google Patents
Heterocyclic compounds and methods of making and using thereof Download PDFInfo
- Publication number
- WO2005042712A3 WO2005042712A3 PCT/US2004/035939 US2004035939W WO2005042712A3 WO 2005042712 A3 WO2005042712 A3 WO 2005042712A3 US 2004035939 W US2004035939 W US 2004035939W WO 2005042712 A3 WO2005042712 A3 WO 2005042712A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- compounds
- making
- heterocyclic compounds
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004286277A AU2004286277A1 (en) | 2003-10-28 | 2004-10-28 | Heterocyclic compounds and methods of making and using thereof |
CA002540460A CA2540460A1 (en) | 2003-10-28 | 2004-10-28 | Heterocyclic compounds and methods of making and using thereof |
JP2006538290A JP2007509966A (en) | 2003-10-28 | 2004-10-28 | Heterocyclic compounds and methods of making and using them |
BRPI0414737-5A BRPI0414737A (en) | 2003-10-28 | 2004-10-28 | heterocyclic compounds and methods of preparing and using these |
EP04817481A EP1678157A4 (en) | 2003-10-28 | 2004-10-28 | Heterocyclic compounds and methods of making and using thereof |
IL174249A IL174249A0 (en) | 2003-10-28 | 2006-03-12 | Heterocyclic compounds and pharmaceutical compositions containing the same |
NO20061292A NO20061292L (en) | 2003-10-28 | 2006-03-21 | Heterosyllic compounds and processes for their preparation and use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN861/CHE/2003 | 2003-10-28 | ||
IN861CH2003 | 2003-10-28 | ||
US61016304P | 2004-09-15 | 2004-09-15 | |
US60/610,163 | 2004-09-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005042712A2 WO2005042712A2 (en) | 2005-05-12 |
WO2005042712A3 true WO2005042712A3 (en) | 2005-07-21 |
Family
ID=34553826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/035939 WO2005042712A2 (en) | 2003-10-28 | 2004-10-28 | Heterocyclic compounds and methods of making and using thereof |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1678157A4 (en) |
JP (2) | JP2007509966A (en) |
KR (1) | KR20070026306A (en) |
AU (1) | AU2004286277A1 (en) |
CA (1) | CA2540460A1 (en) |
IL (1) | IL174249A0 (en) |
NO (1) | NO20061292L (en) |
RU (1) | RU2006112343A (en) |
WO (1) | WO2005042712A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005042712A2 (en) * | 2003-10-28 | 2005-05-12 | Reddy Us Therapeutics, Inc. | Heterocyclic compounds and methods of making and using thereof |
NZ566180A (en) * | 2005-07-29 | 2011-04-29 | Resverlogix Corp | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
PT2118074E (en) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases |
WO2010079431A2 (en) | 2009-01-08 | 2010-07-15 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
EP2408454A2 (en) | 2009-03-18 | 2012-01-25 | Resverlogix Corp. | Novel anti-inflammatory agents |
KR101892987B1 (en) | 2009-04-22 | 2018-08-30 | 리스버로직스 코퍼레이션 | Novel anti-inflammatory agents |
CZ2009358A3 (en) * | 2009-06-03 | 2010-12-15 | C3 Bio Gmbh | 5,7-Disubstituted 3-isopropylpyrazolo[4,3-d]pyrimidines for use as medicament and pharmaceutical compositions comprising thereof |
EP2484349B1 (en) | 2009-09-30 | 2014-04-02 | Shiseido Co., Ltd. | 4-isobutylresorcinol, as heparanase-activity inhibitor, for preventing or suppressing the formation of wrinkles |
JP5992049B2 (en) | 2011-11-01 | 2016-09-14 | レスバーロジックス コーポレイション | Oral immediate release formulations for substituted quinazolinones |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
JP2016507496A (en) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
CN107530356A (en) | 2015-03-13 | 2018-01-02 | 雷斯韦洛吉克斯公司 | For treating the composition and treatment method of complement-associated disease |
CN109475565B (en) | 2016-04-05 | 2021-11-02 | 免疫传感器公司 | cGAS antagonist compounds |
RU2635112C1 (en) * | 2016-12-12 | 2017-11-09 | федеральное государственное автономное образовательное учреждение высшего образования "Южный федеральный университет" | Halides of 1-(4-tert-butylphenyl)-2-{3-[2-(4-fluoro-phenoxy)ethyl]-2-methyl-3h-benzimidazole-1-yl}ethanone with property of rupture cross-linkers of glycated proteins |
CN113507929A (en) * | 2018-12-21 | 2021-10-15 | 阿科利斯制药有限责任公司 | DNA polymerase IIIC inhibitor and application thereof |
CN112300141B (en) * | 2020-10-12 | 2023-04-18 | 贵州大学 | Quinazoline-containing myricetin derivative, and preparation method and application thereof |
WO2022255765A1 (en) * | 2021-06-01 | 2022-12-08 | 주식회사 에즈큐리스 | Novel fluorine-substituted flavonoid derivative, and pharmaceutical composition for preventing or treating allergic diseases, comprising same |
WO2023078252A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6028088A (en) * | 1998-10-30 | 2000-02-22 | The University Of Mississippi | Flavonoid derivatives |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019171A1 (en) * | 1994-01-14 | 1995-07-20 | Cell Therapeutics, Inc. | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
TW399051B (en) * | 1996-01-31 | 2000-07-21 | Ssp Co Ltd | A novel benzoazine thiazolidinedione derivative and pharmaceutical composition for reducing blood glucose |
JPH09268189A (en) * | 1996-01-31 | 1997-10-14 | Ss Pharmaceut Co Ltd | Benzoazine derivative or its salt and medicine containing the same |
US5885997A (en) * | 1996-07-01 | 1999-03-23 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
CZ298812B6 (en) * | 1996-07-01 | 2008-02-13 | Dr. Reddy's Laboratories Limited | Azolidinedione derivatives, process of their preparation, pharmaceutical compositions in which the derivatives are comprised and their use in the treatment of diabetes mellitus and related diseases |
JP4339402B2 (en) * | 1996-12-31 | 2009-10-07 | ドクター・レディーズ・ラボラトリーズ・リミテッド | Novel heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing them, and their use in the treatment of diabetes and related diseases |
DE69815008T2 (en) * | 1997-09-19 | 2004-04-01 | Ssp Co., Ltd. | Alpha-substituted phenylpropionic acid derivatives and medicaments containing them |
US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
WO2005042712A2 (en) * | 2003-10-28 | 2005-05-12 | Reddy Us Therapeutics, Inc. | Heterocyclic compounds and methods of making and using thereof |
-
2004
- 2004-10-28 WO PCT/US2004/035939 patent/WO2005042712A2/en active Application Filing
- 2004-10-28 CA CA002540460A patent/CA2540460A1/en not_active Abandoned
- 2004-10-28 AU AU2004286277A patent/AU2004286277A1/en not_active Abandoned
- 2004-10-28 KR KR1020067005607A patent/KR20070026306A/en not_active Application Discontinuation
- 2004-10-28 EP EP04817481A patent/EP1678157A4/en not_active Withdrawn
- 2004-10-28 RU RU2006112343/04A patent/RU2006112343A/en not_active Application Discontinuation
- 2004-10-28 JP JP2006538290A patent/JP2007509966A/en active Pending
-
2006
- 2006-03-12 IL IL174249A patent/IL174249A0/en unknown
- 2006-03-21 NO NO20061292A patent/NO20061292L/en not_active Application Discontinuation
-
2007
- 2007-10-11 JP JP2007265960A patent/JP2008074858A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6028088A (en) * | 1998-10-30 | 2000-02-22 | The University Of Mississippi | Flavonoid derivatives |
Also Published As
Publication number | Publication date |
---|---|
JP2008074858A (en) | 2008-04-03 |
RU2006112343A (en) | 2007-12-10 |
EP1678157A2 (en) | 2006-07-12 |
EP1678157A4 (en) | 2009-03-18 |
AU2004286277A1 (en) | 2005-05-12 |
NO20061292L (en) | 2006-07-28 |
IL174249A0 (en) | 2006-08-01 |
WO2005042712A2 (en) | 2005-05-12 |
KR20070026306A (en) | 2007-03-08 |
JP2007509966A (en) | 2007-04-19 |
CA2540460A1 (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005042712A3 (en) | Heterocyclic compounds and methods of making and using thereof | |
WO2006024640A3 (en) | Triazolophthalazines | |
PL372926A1 (en) | Piperidine-pyridazones and phthalazones as pde4 inhibitors | |
WO2007044084A3 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
YU21401A (en) | Tetrahydropyridoethers | |
WO2004034990A3 (en) | Methods and compositions for use in treating cancer | |
WO2004092215A3 (en) | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2 | |
WO2006071960A3 (en) | Compositions and methods of treating cell proliferation disorders | |
WO2007016674A3 (en) | 2-aminoaryl pyridines as protein kinases inhibitors | |
UA85559C2 (en) | Aminobenzophenone compounds | |
WO2003082208A3 (en) | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | |
DE69928655D1 (en) | SUBSTITUTED PORPHYRINE | |
WO2005030144A3 (en) | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | |
WO2004066966A3 (en) | Peptide yy analogs | |
EA200601589A1 (en) | 7H-8,9-DIHYDROPYRANO- (2,3-C) IMIDAZO (1,2A) PYRIDINE DERIVATIVES AND THEIR APPLICATION AS AN INHIBITOR SECRETION OF GASTRIC JUICE | |
EA200601855A1 (en) | HERBICIDOACTIVE 3-AMINO-2-THIOMETHYLBENZYLPYRAZOLEES | |
WO2005044200A3 (en) | Methods and compositions for treating mcp-1 related pathologies | |
TR199902257T2 (en) | Tetrahidropirido bile�ikleri | |
WO2004043379A3 (en) | Chemical compounds | |
WO2004099388A3 (en) | Cbl-b polypeptides, complexes and related methods | |
AU2003234198A1 (en) | Novel genes, compositions, and methods for modulating the unfolded protein response | |
WO2002068476A3 (en) | Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders | |
WO2003076897A3 (en) | Multiplexed analysis of cellular responses using endogenous reporter genes | |
DK1196442T3 (en) | VGF polypeptides and methods for the treatment of VGF-related disorders | |
WO2004083241A3 (en) | Btc-interacting proteins and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480031895.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004286277 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 545821 Country of ref document: NZ Ref document number: 2540460 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 174249 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004817481 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067005607 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/003198 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006538290 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/02492 Country of ref document: ZA Ref document number: 200602492 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2004286277 Country of ref document: AU Date of ref document: 20041028 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004286277 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1808/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006112343 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004817481 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0414737 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067005607 Country of ref document: KR |